Steven N. Leonard Office Address: Licensure: Education: Northeastern University Department of Pharmacy Practice 360 Huntington Ave., R218 TF Boston, MA 02115 Email: s.leonard@neu.edu Phone: 617-373-5212 Fax: 617-373-7655 Massachusetts Pharmacist License #PH232420 Indiana Pharmacist License #26021195A Graduate Certificate in Public Health Practice (16 graduate credit hours, Focus on Biostatistics and epidemiology) Wayne State University School of Medicine Detroit, MI May 2008 Doctor of Pharmacy Purdue University School of Pharmacy and Pharmaceutical Sciences West Lafayette, IN December 2004 Bachelor of Science in Pharmacy Purdue University School of Pharmacy and Pharmaceutical Sciences West Lafayette, IN May 2003 Professional Experience: Assistant Professor of Pharmacy Practice Bouvé College of Health Sciences, School of Pharmacy Northeastern University, Boston, MA Clinical Pharmacist Infectious Diseases Brigham and Women s Hospital, Boston, MA September 2008 present September 2008 present Infectious Diseases Pharmacotherapy Fellowship July 2006-July 2008 Anti-Infective Research Laboratory Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University, Detroit, MI Preceptor: Michael Rybak, PharmD, MPH Adjunct Assistant Professor August 2005- May 2006 College of Pharmacy and Health Sciences Butler University, Indianapolis, IN Pharmacy Practice Residency July 2005-June 2006 St. Vincent Indianapolis Hospital, Indianapolis, IN Residency Director: Karie Morrical-Kline, PharmD S. Leonard - 1
Invited Presentations: Abstracts: MRSA therapy: Past, present, and future of combination antimicrobials Presented for the Lambda Kappa Sigma Current Advances in Research Event Northeastern University, Boston, MA, February 29, 2012. MRSA therapy: Beyond just vancomycin 1 g every 12 hours Presented for the Lahey Clinic Annual Clinical Symposium: Infectious Disease, Waltham, MA, September 23, 2011. Does vancomycin still have a role for the treatment of ventilator-associated pneumonia in the ICU? Presented at the Eighth Annual New England Critical Care Pharmacotherapy Symposium, Boston, MA, May 10, 2011. MRSA therapy: Beyond just vancomycin 1 g every 12 hours. Presented for the Conference of Boston Teaching Hospitals Grand Rounds, Boston, MA, September 15, 2010. MRSA therapy: Beyond just vancomycin 1 g every 12 hours. Presented as the Annual Rho Chi Lecture, Northeastern University, Boston, MA, March 25, 2010. New Antimicrobial Agents. Presented as Part of the Fall 2009 Distance Learning Program Infectious Diseases Pharmacotherapy, University of Wisconsin School of Pharmacy, Madison, WI, Fall 2009. Clinical Outcomes of Patients with Bacteremia and Pneumonia caused by hgisa. Presented as part of MRSA Centers for Excellence Fellows Meeting, 48 th ICAAC/46 th IDSA, Washington, DC, October 26, 2008. Clinical Outcomes of Patients with Bacteremia and Pneumonia caused by hgisa. Presented as part of MRSA Centers for Excellence, CME Regional Dinner Meeting, Sponsored by Medical Education Resources Inc. and Collegium and supported through an educational grant provided by Astellas. Townsend Hotel, Birmingham, MI, April 15, 2008. 1. Leonard SN, Supple ME. Comparative Activity of Telavancin (TLV) Combined with Nafcillin (NAF), Imipenem (IMP), and Gentamicin (GEN) against Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic (PK/PD) Model. Presented at the 52 nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, September 9 th 12 th 2012. Abstract A-622. 2. Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, LaPlante KL, Potoski BA, Rybak MJ. Clinical outcomes in patients with heterogeneous vancomycinintermediate Staphylococcus aureus (hvisa). Presented at the 52 nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, September 9 th 12 th 2012. Abstract K-1123. 3. Leonard SN, Murphy K, Zaeem M, Divall MV. The impact of a hybrid learning introductory module on learning outcomes in an anti-infectives therapeutics course. Presented at the 2012 Annual Meeting of the American Association of Colleges of Pharmacy, Kissimmee, FL, July 14 th 18 th 2012. 4. Leonard SN, Gandhi RG, Patel MD. Comparative activity of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus. Presented at the 22 nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), London, UK, March 31 st April 3 rd 2012. Abstract P 1889. S. Leonard - 2
5. Koehler KM, Leonard SN. Synergy Between Daptomycin (DAP) and Nafcillin (NAF) Against Vancomycin (VAN) Intermediate Staphylococcus aureus (VISA). Presented at the 51 st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, September 17 th 20 th 2011. Abstract E-1331. 6. Leonard SN, Rong SL. In Vitro Activity of Combination Vancomycin (VAN) and Nafcillin (NAF) against Heterogeneously Glycopeptide Intermediate Staphylococcus aureus (hgisa). Presented at the 50 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, MA, September 12 th 15 th 2010. Abstract A1-1350. 7. Leonard SN, Szeto YG, Zolotarev M, Grigoryan IV. Comparative In Vitro Activity of Telavancin (TLV), Vancomycin (VAN), and Linezolid (LZD) against Heterogeneously Glycopeptide Intermediate Staphylococcus aureus (hgisa). Presented at the 50 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, MA, September 12 th 15 th 2010. Abstract E-1552. 8. Leonard SN, Rice L. Synergy Between Vancomycin (VAN) and Nafcillin (NAF) against Heterogeneously Glycopeptide Intermediate Staphylococcus aureus (hgisa). Presented at the 49 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, September 12 th 15 th 2009. Abstract E- 1451. 9. Kullar R, Leonard S, Davis S, et al. Validation of a high-trough vancomycin nomogram to achieve trough concentrations of 15 20 mg/l. Presented at the 19 th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Helsinki, Finland, May 16 th 19 th 2009. 10. Leonard SN, Vidaillac C, Rybak MJ. Activity of Telavancin (TLV) Against Staphylococcus aureus (SA) of Varying Vancomycin Susceptibilities in an In Vitro Pharmacokinetic/Pharmacodynamic (PK/PD) Model with Simulated Endocardial Vegetations (SEV). Presented at the 48 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46 th Annual Meeting of the Infectious Diseases Society of America (IDSA), Washington, DC, October 25 th 28 nd 2008. Abstract A-978. 11. Vidaillac C, Leonard SN, Rybak MJ. In Vitro Activity of Ceftaroline vs. Vancomycin against MRSA and hvisa Strains in a Pharmacokinetic/Pharmacodynamic (PK/PD) Model. Presented at the 48 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46 th Annual Meeting of the Infectious Diseases Society of America (IDSA), Washington, DC, October 25 th 28 nd 2008. Abstract A-979. 12. Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ. In Vitro Activity of Ceftaroline (CPT) in Combination against Extended Spectrum β-lactamase (ESBL) Producing Gram-Negative (GN) Bacteria. Presented at the 48 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46 th Annual Meeting of the Infectious Diseases Society of America (IDSA), Washington, DC, October 25 th 28 nd 2008. Abstract C1-161. 13. Vidaillac C, Leonard SN, Rybak MJ. In Vitro Activity and Aminoglycoside Synergy of Ceftaroline (CPT) Against Clinical Isolates of Hospital-Acquired (HA) Methicillin- Resistant Staphylococcus aureus (MRSA). Presented at the 48 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46 th Annual Meeting of the Infectious Diseases Society of America (IDSA), Washington, DC, October 25 th 28 nd 2008. Abstract C1-3719. S. Leonard - 3
14. Leonard SN, Rossi KL, Rybak MJ. Evaluation of the Etest GRD strip for identification of hgisa. Presented at the 18 th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain, April 19 th 22 nd 2008. Abstract P1737. 15. Leonard SN, Rybak MJ. Evaluation of vancomycin and daptomycin against MRSA and hvisa in an in vitro PKPD model with simulated endocardial vegetations. Presented at the 18 th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain, April 19 th 22 nd 2008. Abstract P1057. 16. Leonard SN, Firestine SM, Cheung CM, Kaatz GW, Rybak MJ. Novel DNA Minor Groove Binding (MGB) Agents Active Against Staphylococcus aureus (SA). Presented at the 47 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, September 17 th 20 th, 2007. Abstract F1-2130. 17. Leonard SN, Cheung CM, Rybak MJ. In Vitro Activity of Ceftobiprole (CEF) against Clinical Isolates of Hospital (HA) and Community (CA) Acquired Methicillin Resistant Staphylococcus aureus (MRSA). Presented at the 47 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, September 17 th 20 th, 2007. Abstract E-278. 18. Leonard SN, Kaatz GW, Rucker LR, Rybak MJ. In Vitro Activity of Gemifloxacin (GEMI) Alone and in Combination against Community Associated Methicillin Resistant Staphylococcus aureus (CA-MRSA). Presented at the 47 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, September 17 th 20 th, 2007. Abstract E-1637. 19. Rose WE, Leonard SN, Rybak MJ. In Vitro activity of daptomycin in combination with gentamicin and rifampin against Staphylococcus aureus isolates with reduced daptomycin susceptibility from the bacterial endocarditis clinical trial. Presented at the 47 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, September 17 th 20 th, 2007. Abstract A-794. 20. Martinez J, Rose W, Bhan R, Leonard S, Rybak M. The Impact of Biofilm Production on Outcomes of Patients with Complicated MRSA Bloodstream Infections. Presented at the Wayne State Medical School Research Forum, Detroit, MI, August 23 rd, 2007. 21. Leonard SN, Rybak MJ. Evaluation of Vancomycin and High-Dose Daptomycin against MRSA and Heterogeneous Vancomycin Intermediate Staphylococcus aureus (hvisa) in an In Vitro Pharmacodynamic Model (IVPM) with Simulated Endocardial Vegetations. Presented at the 9 th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections, Heidelberg, Germany, June 14 th 17 th, 2007. 22. Rose WE, Rybak MJ, Leonard SN, Sakoulas G, Kaatz GW, Zervos M, Sheth A., Carpenter CF. Evaluation of daptomycin (D) activity against Staphylococcus aureus (SA) following vancomycin (V) exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations (IVPD-SEV). Presented at the 17 th European Congress of Clinical Microbiology and Infectious Disease, Munich, Germany, March 31 st April 3, 2007. Abstract P2064. S. Leonard - 4
Publications: 1. Leonard SN, Rolek KM. Evaluation of the Combination of Daptomycin and Nafcillin against Vancomycin-Intermediate Staphylococcus aureus. J Antimicrob Chemother 2012. Epub ahead of print 14 November 2012. 2. Leonard SN, Murphy K, Zaeem M, Divall MV. An Introductory Review Module For an Anti-Infectives Therapeutics Course. Am J Pharm Educ 2012;76(7):135. 3. Leonard SN. Synergy between Vancomycin and Nafcillin against Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model. PLoS One 2012;7(7):e42103. 4. Leonard SN, Szeto YG, Zolotarev M, Grigoryan IV. Comparative In Vitro Activity of Telavancin, Vancomycin, and Linezolid against Heterogeneously Vancomycin Intermediate Staphylococcus aureus. Int J Antimicrob Agents 2011;37(6):558-561. 5. Kullar R, Leonard SN, Davis SL, Delgado G, Pogue JM, Wahby KA, Falcione B, Rybak MJ. Validation of the Effectiveness of a Vancomycin Nomogram in Achieving Target Trough Concentrations of 15-20 mg/l Suggested by the Vancomycin Concensus Guidelines. Pharamcotherapy 2011;31(5):441-448. 6. Vidaillac C, Leonard SN, Rybak MJ. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates. Int J Antimicrob Agents 2010;35(6):527-30. 7. Rong SL, Leonard SN. Heterogeneous vancomycin resistance in Staphylococcus aureus: A review of epidemiology, diagnosis, and clinical significance. Ann Pharmacother 2010;44(5):844-50. 8. Vidaillac C, Leonard SN, Rybak MJ. In Vitro Activity of Ceftaroline Against Methicillin-Resistant Staphylococcus aureus and heterogeneous Vancomycin- Intermediate S. aureus Using a Hollow Fiber Model. Antimicrob Agents Chemother 2009;53(11):4712-7. 9. Leonard SN, Vidaillac C, Rybak MJ. Activity of Telavancin Against Staphylococcus aureus of Varying Vancomycin Susceptibilities in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations. Antimicrob Agents Chemother 2009;53(7):2928-2933. 10. Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ. In Vitro Activity of Ceftaroline Alone and in Combination against Clinical Isolates of Resistant Gram- Negative Pathogens, Including β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009;53(6):2360-6. 11. Leonard SN, Rossi KL, Newton KL, Rybak MJ. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother 2009;63(3):489-92. 12. Rose WE, Leonard SN, Rossi KL, Kaatz GW, Rybak MJ. Impact of inoculum and heterogeneous vancomycin intermediate Staphylococcus aureus (hvisa) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2009;53(2):805-7. S. Leonard - 5
13. Leonard SN, Rybak MJ. Evaluation of vancomycin and daptomycin against methicillinresistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. J Antimicrob Chemother 2009;63(1):155-160. 14. Leonard SN, Kaatz GW, Rucker LR, Rybak MJ. Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2008;62(6):1305-10. 15. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sadar HS, Jones RN. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008;46(9):2950-4. 16. Rose WE, Leonard SN, Rybak MJ. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008;52(9):3061-7 17. Leonard SN, Cheung CM, Rybak MJ. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillinresistant Staphylococcus aureus. Antimicrob Agents Chemother 2008;52(8):2974-6. 18. LaPlante KL, Leonard SN, Andes DR, Craig WA, Rybak MJ. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. Antimicrob Agents Chemother 2008;52(6):2156-62. 19. Leonard SN, Rybak MJ. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections. Pharmacotherapy 2008;28(4):458-68. 20. Tsuji BT, Leonard SN, Rhomberg PR, Jones RN, Rybak MJ. Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum. Diagn Microbiol Infect Dis 2008;60(4):441-4. 21. Rose WE, Leonard SN, Sakoulas G, Kaatz GW, Zervos MM, Sheth AA, Carpenter CF, Rybak MJ. Daptomycin Activity against Staphylococcus aureus following Vancomycin Exposure in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations. Antimicrob Agents Chemother 2008;52(3):831-6. Funded Research Grants: 1. Leonard SN (PI) Daptomycin combined with nafcillin against vancomycin intermediate Staphylococcus aureus. Cubist Pharmaceuticals ($11,006, 8/11-6/12). 2. Leonard SN(PI). Comparative Activity of Telavancin Combined with Nafcillin, Imipenem, and Gentamicin against Staphylococcus aureus. Astellas Pharma ($71,672, 8/11-8/12). 3. Leonard SN(PI). Evaluation of Telavancin, Vancomycin, and Linezolid against Heterogeneously Glycopeptide Intermediate Staphylococcus aureus (hgisa). Astellas Pharma ($28, 285, 4/10-12/10). S. Leonard - 6
Awards and Honors: 4. Leonard SN(PI). Evaluation of the Combination of Nafcillin and Vancomycin Against Methicillin Resistant Staphylococcus aureus with Reduced Susceptibility to Glycopeptides. Northeastern University Proposal Development Grant ($5,000, 6/09 5/10). Northeastern University School of Pharmacy Teacher of the Year, 2011. Faculty Inductee, Rho Chi Honor Society, Beta Tau Chapter, Northeastern University, 2010. President s Volunteer Service Award, 2010. American College of Clinical Pharmacy/Ortho-McNeil Infectious Diseases Fellowship award recipient, 2007. $38,000 salary plus travel support and fringe benefits. George McCracken Infectious Diseases Fellow Travel Grant award recipient, 47 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2007. Fellow Travel Grant award recipient, 48 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46 th Annual Meeting of the Infectious Diseases Society of America (IDSA), 2008. Professional Affiliations: American Society for Microbiology Society of Infectious Diseases Pharmacists American College of Clinical Pharmacy American Association of Colleges of Pharmacy Rho Chi Honor Society European Society of Clinical Microbiology and Infectious Diseases 2006-present 2006-present 2007-present 2008-present 2010-present 2011-present S. Leonard - 7